Montelukast Administration Risks and Considerations

Critical Neuropsychiatric Risks

The FDA issued a black box warning in 2020 for montelukast due to serious neuropsychiatric events, which should be carefully weighed against benefits, particularly since montelukast is less effective than alternative therapies like inhaled corticosteroids for asthma and intranasal corticosteroids for allergic rhinitis, as stated by the FDA 1
Suicidal thoughts and actions are among the most serious risks associated with montelukast, according to the FDA's strongest safety warning 1

Headache is the most common side effect overall and was reported most frequently in the Dutch pharmacovigilance database 1

Hepatotoxicity, including hepatitis and elevated liver enzymes, are less common but important adverse effects requiring monitoring, as noted by the FDA 1
Pancreatitis has been reported in clinical trials, though causality has not been definitively established, according to the FDA 1

The FDA explicitly states that montelukast's benefits may not outweigh the risks, especially when disease symptoms are mild and can be adequately treated with other medications, as stated by the FDA 1
Montelukast is less effective than intranasal corticosteroids for allergic rhinitis and should not be considered first-line therapy, according to the FDA 1
For asthma, inhaled corticosteroids are generally more effective as first-line therapy for persistent asthma in children, with studies showing fluticasone provides better asthma control than montelukast, as recommended by the American Academy of Pediatrics 2
The National Asthma Education and Prevention Program (NAEPP) guidelines note that cromolyn, nedocromil, leukotriene receptor antagonists including montelukast, and theophylline have "limited availability for use in the United States, and/or have an increased risk of adverse consequences" 3

Explicitly discuss neuropsychiatric risks with patients and families before starting montelukast, including the potential for suicidal thoughts and behavioral changes, as recommended by the FDA 1
Do not prescribe for mild disease when safer alternatives like intranasal corticosteroids or inhaled corticosteroids are available and appropriate, according to the FDA 1
Monitor for unusual behavioral or mood changes, particularly in the first weeks of therapy, as recommended by the FDA 1
Do not continue therapy without reassessing risk-benefit if any neuropsychiatric symptoms emerge, even if mild, as stated by the FDA 1